Therapeutic Asset Ratings

151 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
MAB HUMANIZED (IGG1) ANTI P43489 (TNR4_HUMAN) (ABBV368) Cancer	AbbVie	P1	C (37)
Mpd-1 Cancer	Pharosgen Co.,Ltd	P1	C (37)
Ntx-1088 Cancer	Nectin Therapeutics Ltd	P1	C (37)
Pan-Neovax Cancer	West China Hospital	P1	C (37)
Rndo-564 Cancer	Rondo Therapeutics	P1	C (37)
rp2 Cancer	Replimune, Inc.	P1	C (37)
Sti-1386 Cancer	Sorrento Therapeutics, Inc.	P1	C (37)
sv-101 Cancer	Williams Cancer Foundation	P1	C (37)
Tavo412 Cancer	Tavotek Biotherapeutics	P1	C (37)
Ttx-080 Cancer	Tizona Therapeutics, Inc	P1	C (37)
wtx212a Cancer	Sun Yat-sen University	P1	C (37)
Idov-Immune Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Early P1	C (34)
rd133 Cancer	Tongji Hospital	Early P1	C (34)
68Ga-FAPI-JNU Cancer	Affiliated Hospital of Jiangnan University	N/A	D (28)
Compound Ciwujia Granules Cancer	Shanghai Municipal Hospital of Traditional Chinese Medicine	N/A	D (28)
CT-100 DiNaMo Cancer	Click Therapeutics, Inc.	N/A	D (28)
HEPARIN Cancer	H. Lee Moffitt Cancer Center and Research Institute	N/A	D (28)
HUMAN PERIPHERAL BLOOD LEUKOCYTES Cancer	A2 Biotherapeutics Inc.		D (28)
LACTULOSE Cancer	Pichamol Jirapinyo, MD, MPH		D (28)
MANNITOL Cancer	Pichamol Jirapinyo, MD, MPH		D (28)
Psma-Hbed-Cc Cancer	IRCCS Azienda Ospedaliero-Universitaria di Bologna		D (28)
Recombinant Fsh Cancer	University of California, San Diego	N/A	D (28)
ROPIVACAINE Cancer	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	N/A	D (28)
Sucralose Cancer	Pichamol Jirapinyo, MD, MPH		D (28)
ft538 Cancer	Masonic Cancer Center, University of Minnesota	P1	D (25)

Showing 126 to 150 of 151 assets

PreviousPage 6 of 7Next